Literature DB >> 17669098

A report card to grade Helicobacter pylori therapy.

David Y Graham, Hong Lu, Yoshio Yamaoka.   

Abstract

Helicobacter pylori causes a serious bacterial infectious disease, and the expectations of therapy should reflect this fact. Increasing antibiotic resistance, especially to clarithromycin, has significantly undermined the effectiveness of legacy triple therapy consisting of a proton pump inhibitor, clarithromycin, and amoxicillin. Current cure rates are consistently below 80% intention-to-treat, the accepted threshold separating acceptable from unacceptable treatment results. Grading clinical studies into effectiveness categories using prespecified criteria would allow clinicians to objectively identify and compare regimens. We offer a therapy report card similar to that used to grade the performance of school children. The intention-to-treat cure rate categories are: F or unacceptable ( 80%), D or poor (81-84%), C or fair (85-89%), B or good (90-95%), and A or excellent (95-100%). The category of "excellent" is based on the cure rates expected with other prevalent bacterial infectious diseases. We propose that only therapies that score "excellent" (grade = A) should be prescribed. Regimens scoring as B or "good" can be used if "excellent" results are not obtainable. In most regions legacy triple therapy should be abandoned as unacceptable. Quadruple therapy and sequential therapy are reasonable alternatives for initial therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669098     DOI: 10.1111/j.1523-5378.2007.00518.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  111 in total

1.  Is quadruple therapy the new triple therapy for H pylori?

Authors:  Christina Korownyk; Michael R Kolber
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

2.  Empiric therapies for Helicobacter pylori infections.

Authors:  David Y Graham; Lori A Fischbach
Journal:  CMAJ       Date:  2011-02-22       Impact factor: 8.262

3.  Vonoprazan-Based Helicobacter pylori Eradication Therapy: Time to Get Kompetitive?

Authors:  Eun Hye Kim; Chan Hyuk Park
Journal:  Dig Dis Sci       Date:  2017-11       Impact factor: 3.199

4.  Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.

Authors:  Xiao-Min Liao; Gao-Hui Nong; Mei-Zu Chen; Xue-Ping Huang; Yun-Yan Cong; Yi-Ying Huang; Bai-He Wu; Jin-Qi Wei
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 5.  Clinical practice: diagnosis and evaluation of dyspepsia.

Authors:  David Yates Graham; Massimo Rugge
Journal:  J Clin Gastroenterol       Date:  2010-03       Impact factor: 3.062

6.  Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication.

Authors:  Abdallah Said Essa; Jennifer Rosenthal Kramer; David Y Graham; Gerhard Treiber
Journal:  Helicobacter       Date:  2009-04       Impact factor: 5.753

7.  Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy.

Authors:  Jingxian Liao; Qing Zheng; Xiao Liang; Wei Zhang; Qinjuan Sun; Wenzhong Liu; Shudong Xiao; David Y Graham; Hong Lu
Journal:  Helicobacter       Date:  2013-04-15       Impact factor: 5.753

Review 8.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

9.  Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates.

Authors:  Seung Bae Yoon; Jae Myung Park; Jong-Yul Lee; Myong Ki Baeg; Chul-Hyun Lim; Jin Soo Kim; Yu Kyung Cho; In Seok Lee; Sang Woo Kim; Myung-Gyu Choi
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 10.  Eradication of Helicobacter pylori infection: which regimen first?

Authors:  Alessandro Federico; Antonietta Gerarda Gravina; Agnese Miranda; Carmela Loguercio; Marco Romano
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.